stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.15
0.88
−3.38%
Follow CAI
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+7 more quarters Free account |
0.00 | 0.00 | 47.41 | 90.19 |
P/S ratio |
9.38 | 5.57 | 5.09 | 8.30 | |
P/FCF ratio |
113.82 | 40.92 | 40.67 | 221.35 | |
P/Operating CF |
170.04 | 153.67 | 177.02 | (390.89) | |
P/B ratio |
13.19 | 8.51 | 8.52 | 14.70 | |
Price to Tangible BV |
13.65 | 8.80 | 8.81 | 15.19 | |
EV/Sales |
8.86 | 5.08 | 4.69 | 7.91 | |
EV/EBITDA |
89.36 | 32.37 | 25.78 | 46.08 | |
EV/Operating CF |
86.50 | 31.28 | 27.53 | 98.89 | |
EV/FCF |
107.53 | 37.34 | 37.44 | 211.17 | |
Quick Ratio |
7.17 | 6.35 | 4.75 | 0.84 | |
Current Ratio |
7.85 | 7.05 | 5.53 | 6.71 | |
Net Debt/EBITDA |
(4.51) | (34.07) | (11.85) | 0.00 | |
Debt/Assets |
33.67% | 32.83% | 31.97% | 31.32% | |
Debt/Equity |
0.66 | 0.64 | 0.66 | 0.00 | |
Asset Turnover |
1.44 | 1.56 | 0.91 | 0.94 | |
Operating CF/Net income |
0.55 | (64.46) | (44.70) | (1.46) | |
Capex/Depreciation |
(1.04) | (1.34) | (3.23) | — | |
Interest Coverage |
7.79 | 0.41 | 2.92 | 2.09 | |
Research and Development Expense of Revenue |
10.87% | 14.49% | 12.27% | 12.29% | |
Selling, General and Administrative Expense of Revenue |
34.37% | 48.46% | 45.62% | 0.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
4.56% | 7.34% | 8.43% | 6.72% | |
Graham Net Nets |
0.06 | 0.09 | 0.08 | 0.05 | |
Graham Number |
0.00 | 0.00 | 4.21 | 0.00 | |
Earnings Yield |
(41.36%) | (42.46%) | 2.11% | 1.11% | |
Free Cash Flow Yield |
0.88% | 2.44% | 2.46% | 0.45% | |
Revenue per Share |
1.04 | 0.77 | 0.93 | 0.97 | |
Operating CF per Share |
0.16 | 0.12 | 0.10 | (0.08) | |
Capex per Share |
(0.02) | (0.04) | (0.08) | 0.00 | |
Free Cash Flow per Share |
0.14 | 0.08 | 0.02 | (0.08) | |
Cash per Share |
2.84 | 2.91 | 2.80 | 0.00 | |
Shareholders Equity per Share |
2.05 | 2.10 | 2.09 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.05 | 2.10 | 2.09 | 0.00 | |
Free Cash Flow |
39.69 | 22.53 | 6.40 | (22.25) | |
Working Capital |
870.66 | 870.28 | 866.39 | 908.32 | |
Capital Expenditures |
(5.09) | (10.34) | (22.07) | — | |
Net Current Asset Value |
449.44 | 445.28 | 419.94 | 451.13 | |
EV/EBIT |
159.45 | 42.55 | 30.28 | 59.28 | |
Capex to Sales |
0.02 | 0.05 | 0.08 | 0.00 | |
Price to Operating Income |
168.78 | 46.63 | 32.89 | 62.14 | |
| Other line items | |||||
Average Receivables |
— | 89.38 | 83.89 | 80.01 | |
Average Payables |
— | 48.80 | 57.36 | 46.42 | |
Average Inventory |
— | 57.93 | 82.20 | 93.84 | |
Average Assets |
562.83 | 581.19 | 1,092.34 | 1,120.10 | |
Average Common Equity |
— | (952.67) | 522.32 | — |
Columns are period end dates · fundamentals updated 4 Nov 2026